Evidence map›Paper›PMID 31801459›Full record

ArticleBMC immunology2019

Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer.

Bonnie J B Lewis, Jade Ville, Megan Blacquiere, Selena Cen, Rolf Spirig, Adrian W Zuercher, Fabian Käsermann, Donald R Branch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Next-generation antibody-based therapies in neurology.Brain : a journal of neurology · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Bonnie J B LewisDepartment of Laboratory Medicine and Pathobiology, University of Toronto, 67 College St., Toronto, Ontario, M5G 2M1, Canada.
Jade VilleCentre for Innovation, Canadian Blood Services, 67 College St., Toronto, Ontario, M5G 2M1, Canada.
Megan BlacquiereCentre for Innovation, Canadian Blood Services, 67 College St., Toronto, Ontario, M5G 2M1, Canada.
Selena CenCentre for Innovation, Canadian Blood Services, 67 College St., Toronto, Ontario, M5G 2M1, Canada.
Rolf SpirigCSL Behring, Research, CSL Biologics Research Center, Wankdorfstrasse 10, 3010, Bern, Switzerland.
Adrian W ZuercherCSL Behring, Research, CSL Biologics Research Center, Wankdorfstrasse 10, 3010, Bern, Switzerland.
Fabian KäsermannCSL Behring, Research, CSL Biologics Research Center, Wankdorfstrasse 10, 3010, Bern, Switzerland.
Donald R BranchDepartment of Laboratory Medicine and Pathobiology, University of Toronto, 67 College St., Toronto, Ontario, M5G 2M1, Canada. don.branch@utoronto.ca.ORCID 0000-0002-8974-2451
CSL (Switzerland) · CHCanadian Blood Services · CAUniversity of Toronto · CAUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-dose intravenous immunoglobulin (IVIg), and more recently, subcutaneously-delivered Ig (SCIg), are used to treat a variety of autoimmune diseases; however, there are challenges associated with product production, availability, access and efficacy. These challenges have provided incentives to develop a human recombinant Fc as a more potent alternative to IVIg and SCIg for the treatment of autoimmune diseases. Recently, a recombinant human IgG1 Fc hexamer (Fc-μTP-L309C) was shown to be more efficacious than IVIg in a variety of autoimmune mouse models. We have now examined its efficacy compared to IVIg and SCIg in the K/BxN mouse model of endogenous, chronic rheumatoid arthritis (RA).

resultUsing the serum-transfer K/BxN model and the endogenous autoimmune model, amelioration of the arthritis was achieved. Effective treatment required high and frequent doses of IVIg, SCIg and Fc-μTP-L309C. However, Fc-μTP-L309C was efficacious at 10-fold lower doses that IVIg/SCIg. Also, arthritis could be prevented when Fc-μTP-L309C was given prior to onset of the arthritis in both the endogenous model and in the serum transfer model.

conclusionsOur results show that Fc-μTP-L309C is a powerful treatment for the prevention and amelioration of severe, chronic arthritis in a true autoimmune mouse model of RA. Thus, the K/BxN endogenous arthritis model should be useful for testing potential therapeutics for RA. Our findings provide rationale for further examination of the treatment efficacy of immunoglobulin-based therapeutics in rheumatoid arthritis.

Indexed as

AnimalsArthritis, RheumatoidChronic DiseaseDisease Models, AnimalHumansImmunoglobulin Fc FragmentsImmunoglobulin GImmunoglobulins, IntravenousImmunologic FactorsMiceTreatment OutcomeImmunoglobulin Fc FragmentsImmunoglobulin GImmunoglobulins, IntravenousImmunologic FactorsAutoimmune diseaseFc-μTP-L309CIntravenous immunoglobulinIVIgRARecombinant Fc hexamerRheumatoid arthritisSCIgSubcutaneous immunoglobulin

Identifiers

PMID31801459
PMCPMC6894239
OpenAlexW2994176244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.